Table 1 VEN combined with epigenetic drugs for R/R AML

Regimen

VEN + HMA

VEN + HMA

VEN + HMA

VEN + ASTX727

VEN + AZA + Chidamide

VEN + AZA + HHT

Study type

Pros

Retro

Retro

N/A

Phase II

Pros

NCT number

N/A

N/A

N/A

N/A

N/A

N/A

Study period

N/A

2012–2022

N/A

N/A

N/A

N/A

Age range (years)

20–67

≥ 18

N/A

46–92

35–64

N/A

Patients number

44

25

136

37

29

231

Response rate

ORR 44%, CR/CRi 40%

ORR 52%, CR/CRi 36%

ORR 58.8%, CR/CRi 44.8%

ORR 53%, CR/CRi 46.7%

ORR 75%, CR/CRi 56.3%

CR/CRi 63.8%

Grade ≥ 3 AEs

N/A

Anemia 80%

N/A

N/A

0

N/A

Follow-up (months)

N/A

N/A

N/A

7

N/A

N/A

Survival

N/A

Median OS 9.6 months, median RFS 10.1 months

1- year OS 49.6%, 2-years OS 39.0%

Median OS not reached

N/A

Median OS not reached, median EFS 7.1 months